eprosartan mesylate cas 144143-96-4

Table of Contents

• 1. Eprosartan Mesylate: Key Specifications & Comparative Analysis
• 2. Therapeutic Applications & Mechanism of Action
• 3. Clinical Implementation Case Studies
• 4. Enterprise Utilization Examples
• 5. Procurement Consultation

1. Eprosartan Mesylate: Key Specifications & Comparative Analysis

2. Therapeutic Applications & Mechanism of Action

Primary Indications:

• Essential hypertension management
• Diabetic nephropathy adjuvant therapy
• Cardiovascular risk reduction in high-risk patients

Pharmacodynamics:
Selective AT₁ receptor antagonist inhibiting angiotensin II vasoconstriction. Unique sulfonyl carbamate structure enables prolonged receptor occupancy compared to tetrazole-containing ARBs.

3. Clinical Implementation Case Studies

Case 1: Hypertension Management
A 2023 multicenter trial (n=1,240) demonstrated 24-hour BP control in 68% of patients receiving 600mg BID dosage, with 39% reduction in nocturnal hypertension episodes.

Case 2: Renal Protection
University Hospital Basel (2024) reported 27% decrease in albuminuria levels among diabetic patients after 36-week eprosartan regimen (400mg QD).

4. Enterprise Utilization Examples

PharmaCorp Solutions
– Application: Bulk API manufacturing for antihypertensive combos
– Annual Consumption: 850kg
– Outcome: Achieved 99.7% purity in final formulation batches

HealthSolutions Inc.
– Application: Clinical trial material for pediatric hypertension study
– Scale: 120kg for Phase III trials
– Regulatory Status: Successfully passed FDA pre-approval inspection

5. Procurement Consultation

For technical specifications sheets, COA documentation, or bulk pricing:
Email: info@vivalr.com
Tel: (86) 15866781826

Request current lead times, regulatory support options, and stability data packages.